As a leading global healthcare company, we engage with a variety of stakeholders, including public officials, healthcare professionals, patient organisations and business partners. In all our interactions, our first priority is to live up to our responsibilities and all regulatory requirements.
Our position on transparency is clear; we will be transparent and accountable for how we operate and the transactions that take place when and where we work. Our position is a part of Novo Nordisk’s company values expressed in the Novo Nordisk Way, in our policies and how we earn and retain trust and confidence.
Collaborations with physicians, research organizations, and healthcare institutions help us to drive innovation and develop new medicines, enhance quality of health education and identify patient needs.
Novo Nordisk supports transparency and is committed to compliance with disclosing our financial relationships related to our collaborations with the medical community as required by relevant decrees and industry guidelines, as well as local laws, including:
We believe that the transparency of financial relationships with healthcare professionals and institutions with whom we collaborate is very important to maintaining trust-based relationships with our patients and the public.
Why are conflict minerals relevant for Novo Nordisk?
The U.S. Securities and Exchange Commission requires companies whose shares are traded on U.S stock exchanges to annually disclose whether the products they manufacture or contract to manufacture contain conflict minerals necessary to the functionality or production of such products that were sourced from the DRC or adjoining countries.
The conflict minerals covered by this rule are:
Novo Nordisk utilises a four-step supply chain country-of-origin inquiry process:
We collaborate with patient organisations in an open and transparent manner to ensure their independence and integrity and our own ethical standards. Our support is based on written agreements that clearly state the purpose of the support as well as the amount and a description of indirect support and any significant non-financial support.
In accordance with industry guidelines in Europe, Novo Nordisk has made details about how we work with patient groups in Europe publicly available. This includes a list of collaboration projects, a short description of the nature of the support, and any financial support.
*European Federation of Pharmaceutical Industries and Associations
Visit the Global Offices page to locate affiliate or use the quick links below.
Quick links to Novo Nordisk affiliates' websites in European region
Disclosure from Novo Nordisk affiliates in the European region with no website
FYROM - Macedonia
Obesity Action Coalition (OAC)
World Federation of Hemophilia
International Association of Patients' Organizations
Additional patient group fundings
If unable to locate specific projects, please consult the relevant Novo Nordisk national affiliate's website.